Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors.

Saved in:
Bibliographic Details
Title: Targeting cancer metabolism: Therapeutic potential of the fatty acid synthase (FASN) inhibitors.
Authors: Nuzzo PV; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Rodrigues S; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Ribeiro CF; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Teixeira IF; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Fanelli GN; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Bleve S; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Ravera F; Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy., Pakula H; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Pederzoli F; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Nanus DM; Department of Medicine, Weill Cornell Medicine, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA; Department of Urology, Weill Cornell Medicine, New York, NY, USA., Loda M; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA; The Broad Institute of Harvard and MIT, Cambridge, MA, USA; The New York Genome Center, New York, NY, USA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: mloda@med.cornell.edu.
Source: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2025 Oct; Vol. 214, pp. 104910. Date of Electronic Publication: 2025 Aug 20.
Publication Type: Journal Article; Review
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0461
DOI:10.1016/j.critrevonc.2025.104910